Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public

Latigo Biotherapeutics (NASDAQ:LTGO) arrived connected nationalist markets with the benignant of reception biotech bankers imagination about. The Thousand Oaks, California, clinical-stage developer priced its IPO astatine $18 per stock and opened astatine $21, raising astir $350 cardinal aft an oversubscribed book. Shares precocious changed hands astatine $19.38. That is up 6.2% from the $18.25 adjacent connected August 7 and 4.62% higher successful the latest session.

The Non-Opioid Pain Thesis

Latigo is simply a stake that selective Nav1.8 inhibition tin seizure a meaningful stock of a U.S. symptom marketplace estimated astatine 250 cardinal prescriptions annually. The S-1 describes the institution arsenic a "clinical-stage biopharmaceutical focused connected non-opioid symptom medicines" with 3 assets:

• LTG-001, a Nav1.8 inhibitor for acute symptom

• LTG-321, a Nav1.8 inhibitor for chronic musculoskeletal symptom

• LTG-418, a next-generation Nav1.8 inhibitor successful preclinical improvement

In a randomized, placebo-controlled abdominoplasty proceedings successful 343 patients crossed 4 U.S. centers, high-dose oral LTG-001 deed its superior endpoint with a 62.1-point SPID48 betterment versus placebo and astir 50% greater analgesic effect than the progressive hydrocodone/acetaminophen comparator arm. The low-dose limb delivered an SPID48 of 37.8 (p=0.003), comparable to the opioid comparator. Latigo believes LTG-001 could go the "first systemic analgesic to receive" an opioid-free statement claim.

Preclinical pharmacology supports the peripheral-only story. The filing reports a 42:1 nerve-to-brain ratio and states that the cause is "believed not to transportation dependency risk."

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and LTGO didn't marque the cut. Grab the names FREE today.

Cash Burn and Going-Concern Language

The S-1 discloses currency and equivalents of $69.4 cardinal arsenic of December 31, 2025. That compares with nett losses of $109.2 cardinal successful 2025 and $61.2 cardinal successful 2024. Operating currency outflows reached $97.6 cardinal past year, up from $51.0 million. The auditor flagged "substantial uncertainty regarding quality to proceed arsenic going concern." The IPO proceeds materially reset that runway.